Cancers 2017, 9(12), 163; doi:10.3390/cancers9120163
Early Postoperative Low Expression of RAD50 in Rectal Cancer Patients Associates with Disease-Free Survival
1
School of Medicine, Western Sydney University, Penrith, NSW 2751, Australia
2
Ingham Institute for Applied Medical Research, Liverpool, NSW 2170, Australia
3
Department of Anatomical Pathology, Liverpool Hospital, Liverpool, NSW 2170, Australia
4
Macarthur Cancer Therapy Centre, Campbelltown Hospital, NSW 2560, Australia
5
Discipline of Medical Oncology, School of Medicine, Western Sydney University, Liverpool, NSW 2170, Australia
6
Department of Medical Oncology, Liverpool Hospital, Liverpool, NSW 2170, Australia
7
Department of Radiation Oncology, Liverpool Hospital, Liverpool, NSW 2170, Australia
8
Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, NSW 2050, Australia
9
Discipline of Pathology, School of Medicine, Western Sydney University, Campbelltown, NSW 2560, Australia
†
These authors contributed equally to this work.
*
Author to whom correspondence should be addressed.
Received: 11 October 2017 / Revised: 24 November 2017 / Accepted: 27 November 2017 / Published: 30 November 2017
(This article belongs to the Special Issue Cancer Biomarkers)
Abstract
Background: Molecular biomarkers have the potential to predict response to the treatment of rectal cancer. In this study, we aimed to evaluate the prognostic and clinicopathological implication of RAD50 (DNA repair protein RAD50 homolog) expression in rectal cancer. Methods: A total of 266 rectal cancer patients who underwent surgery and received chemo- and radiotherapy between 2000 and 2011 were involved in the study. Postoperative RAD50 expression was determined by immunohistochemistry in surgical samples (n = 266). Results: Using Kaplan–Meier survival analysis, we found that low RAD50 expression in postoperative samples was associated with worse disease free survival (p = 0.001) and overall survival (p < 0.001) in early stage/low-grade tumors. In a comparison of patients with low vs. high RAD50 expression, we found that low levels of postoperative RAD50 expression in rectal cancer tissues were significantly associated with perineural invasion (p = 0.002). Conclusion: Expression of RAD50 in rectal cancer may serve as a prognostic biomarker for long-term survival of patients with perineural invasion-positive tumors and for potential use in early stage and low-grade rectal cancer assessment. View Full-TextKeywords:
RAD50; DNA damage response; rectal cancer; prognosis; biomarkers
▼
Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
Share & Cite This Article
MDPI and ACS Style
Ho, V.; Chung, L.; Singh, A.; Lea, V.; Revoltar, M.; Lim, S.H.; Tut, T.-G.; Ng, W.; Lee, M.; de Souza, P.; Shin, J.-S.; Soon Lee, C. Early Postoperative Low Expression of RAD50 in Rectal Cancer Patients Associates with Disease-Free Survival. Cancers 2017, 9, 163.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.